Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2017
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Enanta Pharmaceuticals (ENTA) PT Raised to $82 at Baird
February 8, 2018 6:43 AM ESTBaird raised its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $82.00 (from $46.00) while maintaining a Neutral rating on strong Hep C royalties/pipeline progress.
... MoreEnanta Pharma (ENTA) Tops Q1 EPS by 40c
February 7, 2018 4:02 PM ESTEnanta Pharma (NASDAQ: ENTA) reported Q1 EPS of $0.59, $0.40 better than the analyst estimate of $0.19. Revenue for the quarter came in at $38.1 million versus the consensus estimate of $31.15 million.
Net income for the three months ended December 31, 2017 reflects the $3.8 million, or $0.19 per... More
